Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Exp Dermatol ; 47(7): 1402-1405, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35355315

ABSTRACT

Compared with asymptomatic pulmonary cryptococcosis, secondary cutaneous cryptococcosis may be the first clinical manifestation of disseminated infection but it can be difficult to diagnose clinically. The clinical manifestation of cutaneous cryptococcosis is not pathognomonic, varying from nodules to ulcers and plaques, and frequently mimics other pathologies. This case highlights that an isolated tumour can be an initial manifestation of systemic cryptococcosis in a kidney transplant patient.


Subject(s)
Cryptococcosis , Kidney Transplantation , Neoplasms , Cryptococcosis/diagnosis , Humans , Kidney Transplantation/adverse effects
3.
FEMS Yeast Res ; 20(3)2020 05 01.
Article in English | MEDLINE | ID: mdl-32391887

ABSTRACT

Cryptococcus neoformans is an important invasive fungal pathogen that causes life-threatening meningoencephalitis in humans. Its biological and pathogenic regulatory mechanisms remain largely unknown, particularly due to the presence of those core transcription factors (TFs). Here, we conducted a detailed characterization of the TF Liv4 in the biology and virulence of C. neoformans. Deletion of TF Liv4 protein resulted in growth defect under both normal and stress conditions (such as high temperature and cell wall/membrane damaging agents), drastic morphological damage and also attenuated virulence in C. neoformans. These phenotypic changes might be contributed to transcriptional abnormality in the liv4Δ mutant, in which several cryptococcal genes involved in energy metabolism and cell wall integrity were downregulated. Furthermore, ChIP-seq and ChIP-qPCR assays suggested TF Liv4 might exert its regulatory function in transcription by its activation of RBP1 in C. neoformans. Taken together, our work highlights the importance of TF Liv4 in the growth and virulence of C. neoformans, and it facilitates a better understanding of cryptococcal pathogenesis mechanisms.


Subject(s)
Cryptococcus neoformans/growth & development , Cryptococcus neoformans/genetics , Fungal Proteins/genetics , Gene Expression Regulation, Fungal , Transcription Factors/genetics , Animals , Cryptococcosis/microbiology , Cryptococcus neoformans/pathogenicity , Female , Fungal Proteins/metabolism , Gene Expression Profiling , Macrophages/microbiology , Mice , Mice, Inbred BALB C , Phenotype , Transcription Factors/metabolism , Virulence , Virulence Factors/genetics
4.
Front Immunol ; 10: 1725, 2019.
Article in English | MEDLINE | ID: mdl-31404168

ABSTRACT

Tumor necrosis factor alpha (TNF-α) plays a critical role in the control of cryptococcal infection, and its insufficiency promotes cryptococcal persistence. To explore the therapeutic potential of TNF-α supplementation as a booster of host anti-cryptococcal responses, we engineered a C. neoformans strain expressing murine TNF-α. Using a murine model of pulmonary cryptococcosis, we demonstrated that TNF-α-producing C. neoformans strain enhances protective elements of host response including preferential T-cell accumulation and improved Th1/Th2 cytokine balance, diminished pulmonary eosinophilia and alternative activation of lung macrophages at the adaptive phase of infection compared to wild type strain-infected mice. Furthermore, TNF-α expression by C. neoformans enhanced the fungicidal activity of macrophages in vitro. Finally, mice infected with the TNF-α-producing C. neoformans strain showed improved fungal control and considerably prolonged survival compared to wild type strain-infected mice, but could not induce sterilizing immunity. Taken together, our results support that TNF-α expression by an engineered C. neoformans strain while insufficient to drive complete immune protection, strongly enhanced protective responses during primary cryptococcal infection.


Subject(s)
Cryptococcosis/therapy , Cryptococcus neoformans , Lung Diseases, Fungal/therapy , Tumor Necrosis Factor-alpha/therapeutic use , Animals , Cellular Senescence , Cryptococcus neoformans/genetics , Cryptococcus neoformans/metabolism , Cryptococcus neoformans/pathogenicity , Female , Genes, Synthetic , Leukocytes/metabolism , Lung/immunology , Lung/pathology , Macrophage Activation , Macrophages, Alveolar/immunology , Mice , Mice, Inbred BALB C , Models, Animal , Plasmids/genetics , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Recombinant Proteins/therapeutic use , Specific Pathogen-Free Organisms , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/genetics , Virulence
6.
Lasers Med Sci ; 31(5): 929-36, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27059226

ABSTRACT

The facial flat wart (verruca plana) is one of the most common reasons for dermatology and primary care visits. Although there are many therapeutic modalities, no single therapy has been proven to be completely curative. Case reports and uncontrolled studies suggested that photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA) can effectively treat recalcitrant facial flat warts. A total of 12 patients with recalcitrant facial flat warts were enrolled in the study. ALA gel (10 %) was applied topically to lesions and incubated for 3 h. The lesions were irradiated by an LED light of 630 ± 10 nm at dose levels of 60-100 mW/cm. Clinical assessment was conducted before and after every treatment for up to 24 weeks. Among the ten patients completing three sessions of ALA-PDT, five had complete lesions clearance, and the other five patients were significantly improved. At the 24-week follow-up, the average effective rate was 88.8 %, with no recurrences. No significant side effects were reported. A low-dose topical ALA-PDT regimen using 10 % ALA, 3 h incubation, and a red light source for three treatment sessions are suggested as the optimal scheme for the treatment of recalcitrant flat warts on the face in Chinese patients. Superior efficacy is found in elevated or active period lesions with mild side effects.


Subject(s)
Aminolevulinic Acid/therapeutic use , Face , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Warts/drug therapy , Adult , Asian People , Female , Humans , Male , Middle Aged , Recurrence
7.
Mycopathologia ; 178(1-2): 63-70, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24952011

ABSTRACT

To summarize the epidemiology, clinical features, treatment, and outcome of cryptococcal meningitis (CM) in autoimmune hemolytic anemia (AIHA) patients and to provide a reference for the prevention and control of AIHA complicated with CM, we evaluated five cases of CM in patients with AIHA treated in our hospital from 2003 to 2013 and eight related foreign cases. All of the clinical isolates were Cryptococcus neoformans var. grubii and grouped into the VNI genotype and serotype A. The clinical features exhibit significant features. Headache, nausea, and fever are common symptoms of AIHA complicated with CM. The early clinical manifestations lack specificity, which may lead to delayed diagnosis and treatment. Long-term use of prednisone (≥15 mg day(-1)), poor control of anemia, and splenectomy are risk factors for AIHA complicated with cryptococcal infection. The combination of intravenous amphotericin B and oral 5-fluorocytosine remains the preferred treatment for AIHA complicated with CM.


Subject(s)
Anemia, Hemolytic, Autoimmune/complications , Cryptococcus neoformans/isolation & purification , Meningitis, Cryptococcal/epidemiology , Meningitis, Cryptococcal/pathology , Adolescent , Adult , Aged , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Cryptococcus neoformans/classification , Cryptococcus neoformans/genetics , Female , Flucytosine/therapeutic use , Genotype , Humans , Male , Meningitis, Cryptococcal/drug therapy , Middle Aged , Serogroup , Young Adult
8.
J Dermatol ; 40(10): 854-5, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24033348
SELECTION OF CITATIONS
SEARCH DETAIL
...